2024-01-25 06:14:55 ET
Summary
- Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024.
- Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024.
- The global cystic fibrosis market is expected to reach $37.04 billion by 2030.
- The proprietary Therapeutic Vector Evolution platform has the ability to enhance transgene expression and allow for the ability to overcome limitations observed in prior AAV gene therapies.
4D Molecular Therapeutics (FDMT) has several clinical programs in its pipeline, with one of them being 4D-710 being advanced for the treatment of patients with Cystic Fibrosis [CF]. The most recent update for this program is that it was able to receive Rare Pediatric Disease Designation [RPDD] for the use of this aerosolized treatment for these CF patients. The key thing about this biotech is to specifically not overtake the market itself, but to instead target CF patients who are not able to benefit from currently available CFTR modulators. That is, such patients who don't respond at all to current treatment options. Why I believe that there is value to be unlocked here for shareholders is because the company is expected to release an interim update from the phase 1/2 AEROW clinical study using 4D-710 for these patients in mid-2024....
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024